Frequency of factor V Leiden mutation in Egyptian cases with myocardial infarction

Hematology

Volumn 13, Issue 3, 2008, Pages 170-174

  Settin, Ahmad ^a,c,d,e   Dowaidar, Moataz ^a   El Baz, Rizk ^a   Abd Al Samad, Ayman ^b   El Sayed, Ibrahim ^b   Nasr, Mahmoud ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

^b Cardiology Department   (Egypt)

^c MANSOURA UNIVERSITY CHILDREN S HOSPITAL   (Egypt)

^d QASSIM UNIVERSITY   (Saudi Arabia)

^e NONE   (Egypt)

Author keywords

Egypt; Factor V Leiden mutation; Myocardial infarction; Thrombophilia

Indexed keywords

ADENINE; BLOOD CLOTTING FACTOR 5 LEIDEN; GUANINE;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; EGYPT; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC RISK; GENOTYPE; HEART INFARCTION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERLIPIDEMIA; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; MUTANT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX; SMOKING;

EID: 55849112244     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453308X316158     Document Type: Article

References (24)

1. Glueck CJ, Munjal J, Aregawi D et al. Thrombophilia-hypofibrinolysis and atherothrombotic cardiovascular disease
2. Bertina RM, Koeleman BP, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
3. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-1508.
4. Franco RF, Elion J, Santos SEB, Araújo AG, Tavella MH, Zago MA. Heterogeneous ethnic distribution of the factor V Leiden mutation. Genet Mol Biol 1999; 22: 143-145.
5. Hézard N, Cornillet-Lefebvre P, Gillot L, Potron G, Nguyen P. Multiplex ASA PCR for a simultaneous determination of factor V Leiden gene G->A 20210 prothrombin gene and C->T 677 MTHFR gene mutations. Thromb Haemost 1998; 79: 1054-1055.
6. Ranguelov RD, Rosenthal N, Bromley C, Vasef MA. Detection of factor V leiden and prothrombin gene mutations in patients who died with thrombotic events. Arch Pathol Lab Med 2002; 126: 1193-1196.
7. Bauduer F, Lacombe D. Factor V Leiden, prothrombin 20210A, methylenetetrabydrofolate reductase 677T, and population genetics. Mol Genet Metab 2005; 86: 91-99.
8. Taymaz H, Erarslan S, Oner ET, Alkan T, Agirbasli M, Kirdar B. Sequence variations within the genes related to hemostatic imbalance and their impact on coronary artery disease in Turkish population. Thromb Res 2007; 119: 55-62.
9. Dönmez Y, Kanadasi M, Tanriverdi K et al. Prothrombin 20210GA and factor V Leiden mutations in patients less than 55 years old with myocardial infarction. Jpn Heart J 2004; 45: 505-512.
10. Segev A, Ellis MH, Segev F et al. High prevalence of thrombophilia among young patients with myocardial infarction and few conventional risk factors. Int J Cardiol 2005; 98: 421-424.
11. Lindblad B, Svensson PJ, Dahlbäck B. Arterial and venous thromboembolism with fatal outcome and resistance to activated protein C. Lancet 1994; 343: 917.
12. Kontula K, Ylikorkala A, Miettinen H et al. Arg506Gln-factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995; 73: 558-560.
13. Vallus G, Dlustus B, Acsady G et al. Factor V Leiden and apolipoprotein E genotypes in severe femoropopliteal atherosclerosis with restenosis. Clin Chim Acta 2007; 377: 256-260.
14. Hudecek J, Dobrotová M, Hybenová J et al. Factor V Leiden and the Slovak population. Vnitr Lek 2003; 49: 845-850.
15. Mansourati J, Da Costa A, Munier S et al. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost 2000, 83: 822-825.
16. Holm J, Zoller B, Berntorp E, Erhardt L, Dahlbäck B. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J Intern Med 1996; 239: 221-226.
17. Santos JL, Cruz I, Martin Herrero F, Albarran C, Gonzalez Matas JM, Martin Luengo C. Recurrent coronary thrombosis, factor V Leiden, primary antiphospholipid syndrome and HIV. Rev Esp Cardiol 2004; 57: 997-999.
18. de Paula Sabino A, Ribeiro DD, Carvalho MG, Cardoso J, Dusse LM, Fernandes AP. Factor V Leiden and increased risk for arterial thrombotic disease in young Brazilian patients. Blood Coagul Fibrinolysis 2006; 17: 271-275.
19. Middendorf K, Gohring P, Huehns TY, Seidel D, Steinbeck G, Nikol S. Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction. Am Heart J 2004; 147: 897-904.
20. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: A meta-analysis of published studies. Am Heart J 2003; 146: 948-957.
21. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97: 1037-1041.
22. Roest M, Banga JD, Tempelman MJ et al. Factor V Arg506Gln mutation is not associated with cardiovascular mortality in older women. Am J Epidemiol 1999; 149: 665-670.
23. van de Water NS, French JK, Lund M, Hyde TA, White HD, Browett PJ. Prevalence of factor V Leiden and prothrombin variant G20210A in patients age < 50 years with no significant stenoses at angiography three to four weeks after myocardial infarction. J Am Coll Cardiol 2000; 36: 717-722.
24. Ye Z, Liu EH, Higgins JP et al. Seven haemostatic gene polymorphisms in coronary disease: Meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 1729-1730.